Ontology type: schema:ScholarlyArticle
2002-01-01
AUTHORSC Strupp, U Germing, M Aivado, E Misgeld, R Haas, N Gattermann
ABSTRACTWe examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%). More... »
PAGES1-6
http://scigraph.springernature.com/pub.10.1038/sj.leu.2402330
DOIhttp://dx.doi.org/10.1038/sj.leu.2402330
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1017710244
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/11840256
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anemia, Refractory",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anemia, Refractory, with Excess of Blasts",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Blood Transfusion",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Combined Modality Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Constipation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Evaluation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Fatigue",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myelomonocytic, Chronic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myelodysplastic Syndromes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Peripheral Nervous System Diseases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pilot Projects",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Thalidomide",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Venous Thrombosis",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Strupp",
"givenName": "C",
"id": "sg:person.01001653715.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Germing",
"givenName": "U",
"id": "sg:person.01362464041.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Aivado",
"givenName": "M",
"id": "sg:person.0760154564.99",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760154564.99"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Misgeld",
"givenName": "E",
"id": "sg:person.01137007527.41",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137007527.41"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Haas",
"givenName": "R",
"id": "sg:person.01127414674.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "N",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.bjc.6693515",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044899602",
"https://doi.org/10.1038/sj.bjc.6693515"
],
"type": "CreativeWork"
}
],
"datePublished": "2002-01-01",
"datePublishedReg": "2002-01-01",
"description": "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q\u2212 as sole anomaly and three single aberrations. The median thalidomide dose was 400\u2009mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes \u2a7e1500/\u03bcl, Hb\u2009>\u200911\u2009g/dl and platelets \u2a7e100\u2009000/\u03bcl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).",
"genre": "article",
"id": "sg:pub.10.1038/sj.leu.2402330",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1097065",
"issn": [
"0887-6924",
"1476-5551"
],
"name": "Leukemia",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "16"
}
],
"keywords": [
"hematological improvement",
"myelodysplastic syndrome",
"partial remission",
"efficacy of thalidomide",
"median thalidomide dose",
"RBC transfusion independence",
"treatment of patients",
"complex abnormal karyotype",
"stable disease",
"study patients",
"skin rash",
"progressive disease",
"transfusion independence",
"heart failure",
"thalidomide treatment",
"thalidomide dose",
"IWG criteria",
"minor response",
"treatment response",
"therapeutic benefit",
"patients",
"abnormal karyotype",
"cytogenetic groups",
"sole anomaly",
"normal karyotype",
"major response",
"RAEB",
"remission",
"single aberration",
"syndrome",
"disease",
"weeks",
"months",
"platelets",
"treatment",
"rash",
"response",
"thalidomide",
"CMML",
"karyotype",
"responders",
"dl",
"dose",
"granulocytes",
"median",
"efficacy",
"RAR",
"days",
"Hb",
"improvement",
"failure",
"group",
"aberrations",
"fatigue",
"RA",
"criteria",
"cases",
"summary",
"study",
"benefits",
"anomalies",
"independence"
],
"name": "Thalidomide for the treatment of patients with myelodysplastic syndromes",
"pagination": "1-6",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1017710244"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/sj.leu.2402330"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"11840256"
]
}
],
"sameAs": [
"https://doi.org/10.1038/sj.leu.2402330",
"https://app.dimensions.ai/details/publication/pub.1017710244"
],
"sdDataset": "articles",
"sdDatePublished": "2022-09-02T15:50",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_359.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/sj.leu.2402330"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330'
This table displays all metadata directly associated to this object as RDF triples.
246 TRIPLES
21 PREDICATES
109 URIs
100 LITERALS
28 BLANK NODES